# Biotech Daily Digest — 2025-12-27

**2 items from 1 sources**

## Summary by Source

- Endpoints News: 2 items


## Endpoints News

- **[Biohaven’s ion channel drug fails again, this time in major depressive disorder](https://endpoints.news/biohavens-ion-channel-drug-fails-again-this-time-in-major-depressive-disorder/)**  
  _Fri, 26 Dec 2025 16:12:39 +0000_  
  Biohaven said its potassium channel drug failed a Phase 2 trial in patients with major depressive disorder, the second mid-stage setback for its experimental treatment.

 The Connecticut ...

- **[J&J axes eczema drug from $1.25B acquisition](https://endpoints.news/jj-axes-eczema-drug-from-1-25b-acquisition/)**  
  _Fri, 26 Dec 2025 15:41:06 +0000_  
  Johnson & Johnson said an experimental eczema medicine didn’t meet its standards for efficacy, ending hopes for a drug that the pharma paid $1.25 billion to get in 2024.

 The drug, named JNJ-5939 or NM26 ...
